Literature DB >> 24650975

Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment.

Anupama Goel1, Wen Fan2, Amit A Patel3, Madhuri Devabhaktuni3, Michael L Grossbard2.   

Abstract

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an uncommon variant of classical Hodgkin lymphoma. It is characterized histologically by presence of lymphohistiocytic cells which have B-cell phenotype, are positive for CD19, CD20, CD45, CD79a, BOB.1, Oct.2, and negative for CD15 and CD30. Patients often present with early stage of disease and do not have classical B symptoms. The clinical behavior appears to mimic that of an indolent non-Hodgkin lymphoma more than that of classical Hodgkin disease. The purpose of the present report is to define the biology of NLPHL, review its clinical presentation, and summarize the available clinical data regarding treatment.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hodgkin lymphoma; LP cell; NLPHL; Popcorn cell; Reed Sternberg cells

Mesh:

Year:  2014        PMID: 24650975     DOI: 10.1016/j.clml.2014.01.006

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  3 in total

1.  Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Christopher R Flowers; Loretta J Nastoupil
Journal:  Cancer       Date:  2015-07-06       Impact factor: 6.860

2.  Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival.

Authors:  Rahul R Parikh; Michael L Grossbard; Louis B Harrison; Joachim Yahalom
Journal:  Leuk Lymphoma       Date:  2015-10-02

3.  CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin's Lymphoma.

Authors:  YuanBo Xue; Xun Lai; RuiLei Li; ChunLei Ge; BaoZhen Zeng; Zhen Li; QiaoFen Fu; LiuFang Zhao; SuWei Dong; JinYan Yang; JiYin Guo; QingYin Meng; QingHua Tan; ZhenHui Li; HaiYan Ding; YanLei Zhang; ShaoHui Liu; Alex H Chang; Hong Yao; RongCheng Luo
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.